Optogenetics in the nonhuman primate.

The nonhuman primate brain, the model system closest to the human brain, plays a critical role in our understanding of neural computation, cognition, and behavior. The continued quest to crack the neural codes in the monkey brain would be greatly enhanced with new tools and technologies that can rapidly and reversibly control the activities of desired cells at precise times during specific behavioral states. Recent advances in adapting optogenetic technologies to monkeys have enabled precise control of specific cells or brain regions at the millisecond timescale, allowing for the investigation of the causal role of these neural circuits in this model system. Validation of optogenetic technologies in monkeys also represents a critical preclinical step on the translational path of new generation cell-type-specific neural modulation therapies. Here, I discuss the current state of the application of optogenetics in the nonhuman primate model system, highlighting the available genetic, optical and electrical technologies, and their limitations and potentials.

[1]  Michael Grätzel,et al.  Photoelectrochemical cells , 2001, Nature.

[2]  R. M. Siegel,et al.  Two-Photon Imaging of Calcium in Virally Transfected Striate Cortical Neurons of Behaving Monkey , 2010, PloS one.

[3]  Kenneth P Vives,et al.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  N. Muzyczka,et al.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[6]  C. Gilbert,et al.  Axons and Synaptic Boutons Are Highly Dynamic in Adult Visual Cortex , 2006, Neuron.

[7]  Jessica A. Cardin,et al.  Targeted optogenetic stimulation and recording of neurons in vivo using cell-type-specific expression of Channelrhodopsin-2 , 2010, Nature Protocols.

[8]  Matthew T. Kaufman,et al.  An optogenetic toolbox designed for primates , 2011, Nature Neuroscience.

[9]  Y. Dan,et al.  Burst Spiking of a Single Cortical Neuron Modifies Global Brain State , 2009, Science.

[10]  Ilana B. Witten,et al.  Cholinergic Interneurons Control Local Circuit Activity and Cocaine Conditioning , 2010, Science.

[11]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[12]  L Wang,et al.  MCML--Monte Carlo modeling of light transport in multi-layered tissues. , 1995, Computer methods and programs in biomedicine.

[13]  N. Muzyczka,et al.  Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. , 2005, Human gene therapy.

[14]  R. Tsien,et al.  Adaptation to Synaptic Inactivity in Hippocampal Neurons , 2005, Neuron.

[15]  D T Delpy,et al.  The use of the Henyey–Greenstein phase function in Monte Carlo simulations in biomedical optics , 2006, Physics in medicine and biology.

[16]  B. Sakmann,et al.  Whisker movements evoked by stimulation of single pyramidal cells in rat motor cortex , 2004, Nature.

[17]  P. Marquet,et al.  In vivo local determination of tissue optical properties: applications to human brain. , 1999, Applied optics.

[18]  E. Boyden,et al.  Multiple-Color Optical Activation, Silencing, and Desynchronization of Neural Activity, with Single-Spike Temporal Resolution , 2007, PloS one.

[19]  M. Langlois,et al.  Society of Photo-Optical Instrumentation Engineers , 2005 .

[20]  Xue Han,et al.  High-performance genetically targetable optical neural silencing by proton pumps , 2010 .

[21]  K. Deisseroth,et al.  Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.

[22]  M. Grätzel.  Photoelectrochemical cells : Materials for clean energy , 2001 .

[23]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[24]  A. Kingsman,et al.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. , 2001, Human molecular genetics.

[25]  L Naldini,et al.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector , 1997, Journal of virology.

[26]  M. During,et al.  Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  W. Denk,et al.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Mueller,et al.  Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  O. Isacson,et al.  A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. , 2001, Human gene therapy.

[30]  James M. Wilson,et al.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  G. Schatten,et al.  Transgenic monkeys produced by retroviral gene transfer into mature oocytes. , 2001, Science.

[32]  K. Honda,et al.  Dawn of the evolution of photoelectrochemistry , 2004 .

[33]  M. Federico.  Lentivirus Gene Engineering Protocols , 2010, Methods in Molecular Biology.

[34]  R. Klein,et al.  AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  I. Yaroslavsky,et al.  Optical properties of selected native and coagulated human brain tissues in vitro in the visible and near infrared spectral range. , 2002, Physics in medicine and biology.

[36]  J. Wolfe,et al.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Karl Deisseroth,et al.  Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa , 2010, Science.

[38]  K. Ressler,et al.  Identification of cell-type-specific promoters within the brain using lentiviral vectors , 2007, Gene Therapy.

[39]  Edward S Boyden,et al.  Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  Kwang-Soo Kim,et al.  Genetically engineered dopamine beta-hydroxylase gene promoters with better PHOX2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  H. Okano,et al.  Generation of transgenic non-human primates with germline transmission , 2009, Nature.

[43]  K. Obata,et al.  Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors , 2009, Neuroscience.

[44]  B. Zemelman,et al.  The columnar and laminar organization of inhibitory connections to neocortical excitatory cells , 2010, Nature Neuroscience.

[45]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  T. Vo‐Dinh,et al.  Optical Properties of Tissue , 2003 .

[47]  C. Vite,et al.  Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of β-Glucuronidase-Deficient Mice , 2003, Journal of Virology.

[48]  Murtaza Z Mogri,et al.  Cell Type–Specific Loss of BDNF Signaling Mimics Optogenetic Control of Cocaine Reward , 2010, Science.

[49]  M. Federico.  From lentiviruses to lentivirus vectors. , 2003, Methods in molecular biology.

[50]  Konrad Lehmann,et al.  Visual Function in Mice with Photoreceptor Degeneration and Transgenic Expression of Channelrhodopsin 2 in Ganglion Cells , 2010, The Journal of Neuroscience.

[51]  S. Sternson,et al.  AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training , 2010, Nature Neuroscience.

[52]  K. Deisseroth,et al.  Millisecond-timescale, genetically targeted optical control of neural activity , 2005, Nature Neuroscience.

[53]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[54]  Michael A. Henninger,et al.  High-Performance Genetically Targetable Optical Neural Silencing via Light-Driven Proton Pumps , 2010 .

[55]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[58]  Karl Deisseroth,et al.  Optogenetics in Neural Systems , 2011, Neuron.

[59]  Niraj S. Desai,et al.  Activity-dependent scaling of quantal amplitude in neocortical neurons , 1998, Nature.

[60]  Zeger Debyser,et al.  Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.

[61]  Jacob G. Bernstein,et al.  Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain , 2009, Neuron.

[62]  J. Bachevalier,et al.  Towards a transgenic model of Huntington’s disease in a non-human primate , 2008, Nature.

[63]  Edward M. Callaway,et al.  Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types , 2009, Frontiers in neural circuits.

[64]  N. Muzyczka.  Use of adeno-associated virus as a general transduction vector for mammalian cells. , 1992, Current topics in microbiology and immunology.

[65]  R. Klein,et al.  Adeno-associated virus vectors: activity and applications in the CNS , 2000, Journal of Neuroscience Methods.

[66]  T. Murphy,et al.  Automated light-based mapping of motor cortex by photoactivation of channelrhodopsin-2 transgenic mice , 2009, Nature Methods.

[67]  Nathan C. Klapoetke,et al.  A High-Light Sensitivity Optical Neural Silencer: Development and Application to Optogenetic Control of Non-Human Primate Cortex , 2010, Front. Syst. Neurosci..

[68]  Xue Han,et al.  Prosthetic systems for therapeutic optical activation and silencing of genetically targeted neurons , 2008, SPIE BiOS.

[69]  Ilana B. Witten,et al.  Witten Conditioning Cholinergic Interneurons Control Local Circuit Activity and Cocaine , 2011 .